Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Stock at a glance

Equity story
Since our foundation in 1993, we have offered investors direct access to a select portfolio of promising, fast growing and profitable biotech companies listed on stock markets around the world. Thanks to our strong track record over the years and our systematic strategy and clear focus, we have become one of the world’s largest biotech investors.

Biotechnology is one of the most attractive of any sector today with estimated annual growth in the double-digits. Mega trends such as increasing life expectancy and a westernized diet and lifestyle are powerful growth drivers. These mega trends have led to a tremendous increase in healthcare costs, which, in turn, only amplifies the need for more efficient and effective drugs.

Furthermore, many pharmaceutical giants are confronted with deep cuts in revenue streams as a result of patent expirations. They are now purchasing innovative biotech products in an attempt to replenish product pipelines and have been willing to pay top dollar in these deals.

Meanwhile every second drug approved today stems from the labs of a biotech company and many biotech firms have been reporting strong sales and profit growth. The biotech industry has obviously come of age and reached a certain level of maturity.

Facts & Figures

FoundationNovember 9, 1993,
Schaffhausen, Switzerland
Issue price adj.
November 15, 1993
 CHF 4.75
 Official Listing  Switzerland: December 27, 1993
Germany: December 10, 1997
Share structureCHF 11.08 mn nominal, 55 400 000 
registered shares with a par value of 
CHF 0.2
Shareholders, free float as at 30.09.2025

Institutional and private investors

100% free-float

Security number Switzerland3 838 999
Security number GermanyA0NFN3
ISINCH0038389992
Ticker BloombergSwitzerland: BION SW
Germany: BBZA GY
Ticker ReutersSwitzerland: BION.S
Germany: BION.DE
Type / asset classInvestment company / equity
Investment styleLong only, long term
Index membershipSwiss All Share Index, SPI Index, 
SPI ESG Index, SPI EXTRA Index, 
SPI ex SLI Index, SXI LIFE SCIENCES Index, 
SXI Bio+Medtech Index
BenchmarkNasdaq Biotech Index (NBI) TR
Management FeeAll-in-Fee: 1.1% p.a.

 

Analyst Coverage

InstituteAnalyst
Baader HelveaThomas Meyer 
EdisonJoanne Collins
Kepler CheuvreuxNicolas Pauillac
Oddo BHFOussama Denguir
Panmure LiberumCallum Stokeld
Pareto SecuritiesMarcus Wieprecht 
SEBMartin Parkhoi